Quick Summary
The National Pharmaceutical Pricing Authority (NPPA) has notified the retail prices of several new drug formulations, including widely prescribed combinations for pain relief and diabetes management. The order, issued on September 15, 2025, under the Drugs (Prices Control) Order, 2013 (DPCO), fixes
Daily Limit Reached
You have reached your daily limit of 2 Free News
Subscribe to CCI PRO for unlimited access
Why Upgrade to CCI PRO?
- No Ads
- WhatsApp Broadcasts
- Daily E-Newsletter
- Unlimited News Access
BEST VALUE
2 YEAR PLAN
3,499
(Inclusive of GST)
1 YEAR PLAN
1,999
(Inclusive of GST)
Buy CCI PRO Now
Already a PRO member? Login here for an ad-free experience.
FAQ :
The NPPA has fixed the maximum retail prices (MRPs) for several new drug formulations, particularly combination drugs used for pain relief and diabetes management.
The maximum retail prices fixed by the NPPA are exclusive of Goods and Services Tax (GST). Manufacturers can add GST only if it is payable.
Examples include Aceclofenac, Paracetamol & Thiocolchicoside tablets, Ibuprofen & Paracetamol suspension, and various combinations of Dapagliflozin, Glimepiride, Metformin, Sitagliptin, and Empagliflozin.
Any violation, including overcharging, will result in the recovery of the overcharged amount along with interest, as per the Essential Commodities Act, 1955.
The move is intended to prevent the overpricing of essential combination drugs, ensuring affordability and transparency in the pharmaceutical market for patients managing chronic conditions.
CAclubindia
